Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor

OBJECTIVES: Sabatolimab is a humanized monoclonal antibody (hIgG4, S228P) directed against human T-cell immunoglobulin domain and mucin domain-3 (TIM-3). Herein, we describe the development and characterization of sabatolimab. METHODS: Sabatolimab was tested for binding to its target TIM-3 and block...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwartz, Stephanie, Patel, Nidhi, Longmire, Tyler, Jayaraman, Pushpa, Jiang, Xiaomo, Lu, Hongbo, Baker, Lisa, Velez, Janelle, Ramesh, Radha, Wavreille, Anne-Sophie, Verneret, Melanie, Fan, Hong, Hu, Tiancen, Xu, Fangmin, Taraszka, John, Pelletier, Marc, Miyashiro, Joy, Rinne, Mikael, Dranoff, Glenn, Sabatos-Peyton, Catherine, Cremasco, Viviana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525012/
https://www.ncbi.nlm.nih.gov/pubmed/36196369
http://dx.doi.org/10.1093/immadv/ltac019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525012/
https://www.ncbi.nlm.nih.gov/pubmed/36196369
http://dx.doi.org/10.1093/immadv/ltac019

Ejemplares similares